Posts

Novartis’s Lp(a) drug sharply lowered the biomarker but did not prevent cardiovascular events

Pelacarsen’s trial miss clouds the future of Lp(a) cholesterol drugs

Novartis drops VHB937 ALS program after Phase 2 failure

Novartis board faces investor scrutiny after M&A misfires and R&D setbacks

Novartis’s Triple Clinical Setback Hits Shares and Weighs on Pharma Peers

Novartis’s Pelacarsen Fails to Reduce Cardiovascular Risk in Phase 3 Trial

Novartis stock drops after Avidity centerpiece fails Phase 3 trial

Novartis drops after Avidity-acquired muscle-drug trial miss

Lp(a): Why biotech is betting on the “diabolical” molecule